By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ViiV Healthcare 

Five Moore Drive

Research Triangle Park  North Carolina  27709-3398  U.S.A.
Phone: 877-844-8872 Fax: n/a


Company News
ViiV Healthcare Announces Superior Efficacy Of Dolutegravir Versus Lopinavir/Ritonavir In Second-Line HIV Treatment In Resource-Limited Settings 7/25/2017 12:09:45 PM
bioMONTR Labs Release: Company Announces Laboratory Service Agreements With ViiV Healthcare 1/25/2017 8:56:46 AM
Primary Endpoint Met in ViiV Healthcare's Two Phase III Trials of Two-Drug HIV Treatment Regimen 12/20/2016 6:47:44 AM
More Changes at GlaxoSmithKline (GSK) as ViiV Healthcare CEO Steps Down, New Leader Named 12/6/2016 5:35:22 AM
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016 8:21:30 AM
ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV 7/18/2016 6:10:34 AM
ViiV Healthcare Announces FDA Approval To Lower The Weight Limit For Dolutegravir In Children And Adolescents Living With HIV 6/10/2016 9:36:25 AM
ViiV Healthcare And The International Association Of Providers Of AIDS Care (IAPAC) To Collaborate On Fast-Track Cities 5/31/2016 10:04:51 AM
ViiV Healthcare, Medicines Patent Pool Extend Licence For Dolutegravir To All Lower Middle-Income Countries 4/25/2016 7:25:58 AM
ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir 2/25/2016 6:06:48 AM